Theravance Biopharma, Inc. (TBPH) is an innovative biopharmaceutical company committed to the discovery, development, and commercialization of small-molecule medicines. Drawing from a depth of experience in drug discovery and development, the team at TBPH is focused on advancing a series of unique programs to address serious chronic conditions, including respiratory diseases, infectious diseases and gastrointestinal disorders.
Founded in 1996 and headquartered in South San Francisco, California, the company prides itself on its entrepreneurial and science-driven culture, which leans heavily on the principle of scientific excellence and a commitment to fully exploring and leveraging their primary technology platform: organ-selective medicine.
Organ-selective medicine is a novel approach that targets drug molecules to specific organs or tissues in the body, thereby significantly increasing their therapeutic benefits, while virtually eliminating unwanted side effects.
Theravance Biopharma has a notable track record of success in drug discovery. It has brought to market two respiratory drugs, namely Vibativ and Yupelri, in partnership with global leaders. Vibativ treats hospital-acquired bacterial pneumonia, while Yupelri is used in chronic obstructive pulmonary disease. Both drugs have earned considerable commercial success and are substantial contributors to the company's revenues.
The pipeline of Theravance Biopharma is also quite robust and diversified. It includes several early and late-stage assets across multiple therapeutic areas. They're also developing a once-daily, single-inhaler triple therapy for patients with COPD, in partnership with Innoviva, Inc.
In 2020, Theravance Biopharma demonstrated high business resilience in light of the COVID-19 pandemic. The company continues to reach new clinical milestones, enroll patients into its clinical trials, and progress its research programs.
Moreover, the company sustains a strong balance sheet and has put strategic actions in place to reduce operating expenses while preserving key R&D projects. Their ability to adapt, innovate, and grow amidst turbulent times is commendable, leading them a step closer to their mission of transforming the treatment of patients suffering from serious illnesses.
In conclusion, with an experienced team, state-of-the-art technology, strategic partnerships, and a strong product portfolio, Theravance Biopharma, Inc. is solidly positioned for future growth. As they continue to evolve and advance their research, their work stands to bring significant improvements to patients’ lives, while also delivering value to their shareholders.